Akari Therapeutics Plc (AKTX) financial statements (2020 and earlier)

Company profile

Business Address 24 WEST 40TH STREET
NEW YORK, NY 10018
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments696
Cash and cash equivalents696
Restricted cash and investments 0
Receivables0 
Other undisclosed current assets10
Total current assets:706
Noncurrent Assets
Property, plant and equipment00
Intangible assets, net (including goodwill)0 
Intangible assets, net (excluding goodwill)0 
Restricted cash and investments0 
Total noncurrent assets:00
TOTAL ASSETS:706
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities52
Accounts payable41
Accrued liabilities00
Employee-related liabilities 0
Due to related parties 0
Other undisclosed current liabilities16(0)
Total current liabilities:211
Noncurrent Liabilities
Liabilities, other than long-term debt 0
Other liabilities 0
Other undisclosed noncurrent liabilities00
Total noncurrent liabilities:00
Total liabilities:212
Stockholders' equity
Stockholders' equity attributable to parent495
Common stock181
Additional paid in capital8734
Accumulated other comprehensive income0 
Accumulated deficit(57)(30)
Total stockholders' equity:495
TOTAL LIABILITIES AND EQUITY:706

Income statement (P&L) ($ in millions)

12/31/2015
12/31/2014
Revenues
(Financial Services Revenue)
 1
Cost of revenue
(Financial Services Costs)
(23) 
Gross profit:(23)1
Operating expenses(31)(10)
Other undisclosed operating income (loss)23(1)
Operating loss:(31)(10)
Nonoperating income (expense)(15)1
Other nonoperating income 1
Interest and debt expense(3) 
Loss from continuing operations before equity method investments, income taxes:(48)(10)
Other undisclosed income from continuing operations before income taxes3 
Net loss available to common stockholders, diluted:(45)(10)

Comprehensive Income ($ in millions)

12/31/2015
12/31/2014
Net loss:(45)(10)
Comprehensive loss:(45)(10)
Other undisclosed comprehensive income, net of tax, attributable to parent0 
Comprehensive loss, net of tax, attributable to parent:(45)(10)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: